Get the Stockscreener App
1,100.00
0.09%
1.43
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,100.00, with a volume of 434.30K.
It is up +0.09% in the last 24 hours and up +3.24% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,098.57
Open:
$1112.24
24h Volume:
434.30K
Relative Volume:
0.14
Market Cap:
$981.38B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
39.60
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-2.64%
1M Performance:
+3.24%
6M Performance:
+2.14%
1Y Performance:
+44.16%
1-Day Range:
$1,095.23
$1,119.45
1-Week Range:
$1,088.65
$1,146.68
52-Week Range:
$623.78
$1,182.73
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,100.52 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
229.69 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
226.88 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
113.72 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
148.06 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Is Eli Lilly and Company (LLY) among the Best Longevity and Anti-Aging Stocks to Buy? - Insider Monkey
Cantor Fitzgerald reiterates Eli Lilly stock Overweight rating at $1,230 - Investing.com
Lilly bets up to $800M for BioArctic’s brain delivery tech - BioSpace
Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis - GlobeNewswire Inc.
Eli Lilly (LLY) Partners with BioArctic for Neurodegeneration Tr - GuruFocus
BioArctic, Eli Lilly ink deal to combine drug-delivery tech with Lilly compound - Investing.com Canada
BioArctic and Lilly Sign Research and Collaboration Agreement Combining Lilly Compound With BioArctic's BrainTransporter Technology - Moomoo
Eli Lilly StockWeekly outlook with earnings and obesity focus - AD HOC NEWS
Eli Lilly Stock (LLY) Opinions on Pipeline Expansions and Regulatory Risks - Quiver Quantitative
3 Reasons to Buy Eli Lilly Stock - AOL.com
AI Rewrites Drug Discovery: Eli Lilly and Twist Bioscience Chart Two Distinct Industrialization Paths - NAI500
New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway - Morningstar
Eli Lilly & Co (NYSE:LLY): A Dividend Growth Gem with Strong Fundamentals - ChartMill
Charles River collaborates with Lilly TuneLab platform - Yahoo Finance
Eli Lilly cuts 340B discounts for hospitals resisting its claims data submission policy - Fierce Healthcare
Why Are Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) Driving S&P 500 Healthcare Focus? - Kalkine Media
Eli Lilly Weight Drug TM Deal Too Secretive, Ind. Judge Says - Law360
Eli Lilly and Company (LLY) is one of the Best Growth Stocks to Buy According Ray Dalio - Yahoo Finance
UBS issues Eli Lilly-linked autocallable notes (AMUB) maturing June 2029 - Stock Titan
UBS (AMUB) offers Trigger Autocallable Notes linked to Eli Lilly — 2029 maturity - Stock Titan
UBS AG offers autocallable notes linked to Eli Lilly (AMUB) due 2028 - Stock Titan
UBS (AMUB) launches Trigger Autocallable Notes tied to Eli Lilly shares - Stock Titan
Eli Lilly & Co. stock outperforms competitors despite losses on the day - MarketWatch
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound - MarketBeat
Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs - Business Wire
Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise - Business Wire
What’s Happening at Eli Lilly and Company (LLY)’s Pipeline? Early Signals Emerge - Insider Monkey
Parkland School District rejects Eli Lilly tax break amid major budget challenges - WFMZ.com
Axcelead DDP Joins Lilly TuneLab to Advance AI Drug Discovery - Business Wire
Cathie Wood’s ARK sells Robinhood and Roku stock, buys Eli Lilly - Investing.com Nigeria
Eli Lilly Urges Full Fed. Circ. To Scrap Teva's $177M IP Win - Law360
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus
Eli Lilly (LLY) Sees Purchase of 41,000 Shares by ARK Investment - GuruFocus
Eli Lilly Stock's Trillion-Dollar Question - Yahoo Finance
Eli Lilly: Pharma With Unstoppable Momentum Targets Pain With Latest M&A Deal (NYSE:LLY) - Seeking Alpha
Jim Cramer on Eli Lilly: “I Want You to Stay in the Stock” - Insider Monkey
Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished - Yahoo Finance
FDA Approves New Eight-Week Maintenance Dosing Regimen for Eli Lilly’s (LLY) EBGLYSS - Yahoo
Eli Lilly buys 4E to deepen non-opioid pain push - The Pharma Letter
Parkland School Board will not provide tax break for Eli Lilly amid strained budget cycle - The Morning Call
Can Retatrutide Extend Eli Lilly and Co (LLY)’s Lead in Weight Loss Market? - Yahoo Finance
Eli Lilly’s M&A spree continues with acquisition of non-opioid pain drugmaker 4E - Fierce Biotech
Lilly Acquires 4E Therapeutics To Advance Non-Opioid Chronic Pain Treatments - Pulse 2.0
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock? - Yahoo Finance
Lilly Acquires 4E Therapeutics to Advance Non-Opioid Chronic Pain Pipeline - citybiz
Lilly buys non-opioid pain drugmaker 4E - BioPharma Dive
Eli Lilly’s hottest drugs face a quiet new threat - thestreet.com
Lilly buys another pain biotech; FDA sets decision for once-weekly PrEP pill - Endpoints News
Eli Lilly Acquires 4E Therapeutics for Undisclosed Amount >LLY - Moomoo
4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic Pain - PR Newswire
Eli Lilly & Co. (NYSE:LLY): High Growth Momentum Meets Strong Technical Breakout Setup - ChartMill
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):